Literature DB >> 25647525

Viremic and Virologically Suppressed HIV Infection Increases Age-Related Changes to Monocyte Activation Equivalent to 12 and 4 Years of Aging, Respectively.

Thomas A Angelovich1, Anna C Hearps, Anna Maisa, Genevieve E Martin, Gregor F Lichtfuss, Wan-Jung Cheng, Clovis S Palmer, Alan L Landay, Suzanne M Crowe, Anthony Jaworowski.   

Abstract

BACKGROUND: Chronic inflammation and immune activation occur in both HIV infection and normal aging and are associated with inflammatory disease. However, the degree to which HIV influences age-related innate immune changes, and the biomarkers which best reflect them, remains unclear. METHODS AND
RESULTS: We measured established innate immune aging biomarkers in 309 individuals including 88 virologically suppressed (VS) and 52 viremic (viral load ≤ and >50 copies per milliliter, respectively) HIV-positive individuals. Levels of soluble (ie, CXCL10, soluble CD163, neopterin) and cellular (ie, proportions of inflammatory CD16 monocytes) biomarkers of monocyte activation were increased in HIV-positive individuals and were only partially ameliorated by viral suppression. Viremic and VS HIV-positive individuals show levels of age-related monocyte activation biomarkers that are similar to uninfected controls aged 12 and 4 years older, respectively. Viremic HIV infection was associated with an accelerated rate of change of some monocyte activation markers (eg, neopterin) with age, whereas in VS individuals, subsequent age-related changes occurred at a similar rate as in controls, albeit at a higher absolute level. We further identified CXCL10 as a robust soluble biomarker of monocyte activation, highlighting the potential utility of this chemokine as a prognostic marker. IMPLICATIONS: These findings may partially explain the increased prevalence of inflammatory age-related diseases in HIV-positive individuals and potentially indicate the pathological mechanisms underlying these diseases, which persist despite viral suppression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25647525     DOI: 10.1097/QAI.0000000000000559

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

Review 1.  Fate of microglia during HIV-1 infection: From activation to senescence?

Authors:  Natalie C Chen; Andrea T Partridge; Christian Sell; Claudio Torres; Julio Martín-García
Journal:  Glia       Date:  2016-11-26       Impact factor: 7.452

Review 2.  Role of immune activation in progression to AIDS.

Authors:  Netanya S Utay; Peter W Hunt
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 3.  Frailty in HIV: Epidemiology, Biology, Measurement, Interventions, and Research Needs.

Authors:  Damani A Piggott; Kristine M Erlandson; Kevin E Yarasheski
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

Review 4.  Assessing immune aging in HIV-infected patients.

Authors:  Victor Appay; Delphine Sauce
Journal:  Virulence       Date:  2016-06-16       Impact factor: 5.882

5.  Circulating inflammatory monocytes contribute to impaired influenza vaccine responses in HIV-infected participants.

Authors:  Varghese K George; Suresh Pallikkuth; Rajendra Pahwa; Lesley R de Armas; Stefano Rinaldi; Li Pan; Savita Pahwa
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

6.  Plasma acylcarnitines and progression of carotid artery atherosclerosis in HIV infection.

Authors:  Simin Hua; Justin M Scott; David B Hanna; Sabina A Haberlen; Sanjiv J Shah; Howard N Hodis; Alan L Landay; Jason M Lazar; Jorge R Kizer; Bing Yu; Wendy S Post; Kathryn Anastos; Robert C Kaplan; Clary B Clish; Qibin Qi
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.632

7.  The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease.

Authors:  Signar Mäkitalo; Åsa Mellgren; Ellen Borgh; Lena Kilander; Tobias Skillbäck; Henrik Zetterberg; Magnus Gisslén
Journal:  AIDS Res Ther       Date:  2015-07-14       Impact factor: 2.250

8.  Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors.

Authors:  Alison Castley; Leah Williams; Ian James; George Guelfi; Cassandra Berry; David Nolan
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

9.  Elevated ischemic stroke risk among women living with HIV infection.

Authors:  Felicia C Chow; Susan Regan; Markella V Zanni; Sara E Looby; Cheryl D Bushnell; James B Meigs; Steven K Grinspoon; Steve K Feske; Virginia A Triant
Journal:  AIDS       Date:  2018-01-02       Impact factor: 4.177

10.  Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset.

Authors:  Mickaël J Ploquin; Yoann Madec; Armanda Casrouge; Nicolas Huot; Caroline Passaes; Camille Lécuroux; Asma Essat; Faroudy Boufassa; Béatrice Jacquelin; Simon P Jochems; Gaël Petitjean; Mathieu Angin; Kathleen Gärtner; Thalía Garcia-Tellez; Nicolas Noël; Thijs Booiman; Brigitte D Boeser-Nunnink; Pierre Roques; Asier Saez-Cirion; Bruno Vaslin; Nathalie Dereudre-Bosquet; Françoise Barré-Sinoussi; Mathilde Ghislain; Christine Rouzioux; Olivier Lambotte; Matthew L Albert; Cécile Goujard; Neeltje Kootstra; Laurence Meyer; Michaela C Müller-Trutwin
Journal:  PLoS Pathog       Date:  2016-08-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.